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Evidence indicates that noradrenaline elicits anti-inflammatory actions in the central nervous system
(CNS), and plays a neuroprotective role where inflammatory events contribute to pathology. Here we
examined the ability of pharmacological enhancement of central noradrenergic tone to impact upon
activation of the IL-1 system in rat brain. Treatment with the noradrenaline reuptake inhibitor reboxetine
combined with the a2-adrenoceptor antagonist idazoxan induced expression of IL-1b as well as its
negative regulators, IL-1 receptor antagonist (IL-1ra) and IL-1 type II receptor (IL-1RII) in rat cortex. The
ability of reboxetine/idazoxan treatment to activate the IL-1 systemwas mediated by b-adrenoceptors, as
the aforementioned effects were blocked by the b-adrenoceptor antagonist propranolol. Moreover,
administration of the brain penetrant b2-adrenoceptor agonist clenbuterol induced expression of IL-1b,
IL-1ra and IL-1RII in rat brain. This action was selective to the IL-1 system, as other inflammatory
cytokines including TNF-a, IL-6 or IFN-g were not induced by clenbuterol. Induction of IL-1b was
accompanied by activation of NFkB and of the MAP kinase ERK, and clenbuterol also induced expression
of the IL-1b-inducible gene CINC-1. The ability of clenbuterol to activate the IL-1 system was blocked by
propranolol, and was mimicked by the highly selective b2-adrenoceptor agonist formoterol. Despite the
ability of clenbuterol to activate the central IL-1 system, it largely combated the neuroinflammatory
response induced by systemic inflammatory stimulus (bacterial lipopolysaccharide; LPS). Specifically,
whilst the ability of clenbuterol to induce expression of IL-1RII and IL-1Ra was maintained following the
inflammatory challenge, its ability to induce IL-1b was reduced. In addition, clenbuterol suppressed LPS-
induced expression of the inflammatory cytokines TNF-a and IL-6, the inflammatory chemokines
RANTES and IP-10, the co-stimulatory molecules CD40 and ICAM-1. Thus overall, clenbuterol suppresses
the innate inflammatory response in rat brain.
 2010 Elsevier Ltd. All rights reserved.1. Introduction immunosuppressive environment of the brain (Feinstein et al., 2002;Neuroinflammation, characterised by inappropriate microglial
activation and inflammatorymediator production, contributes to the
pathophysiology of neurodegenerative states such as Alzheimer’s
disease, Parkinson’s disease and ischaemic stroke (Allan et al., 2005;
Block et al., 2007; Heneka and O’Banion, 2007). Evidence indicates
that the neurotransmitter noradrenaline has anti-inflammatory
properties, and plays an important role in maintaining theollege Institute of Neurosci-
and. Tel.: þ353 1 8968575;
All rights reserved.Heneka et al., 2002;Marien et al., 2004).Noradrenergic innervation is
widespread throughout the brain, and following its release
noradrenaline can reach proximal glial cells (Aoki, 1992) and modu-
late glial function by activating b2-adrenoceptors (Mori et al., 2002).
Interleukin-1b (IL-1b) has been implicated as a key mediator of
neuroinflammation (see Allan et al., 2005). Whilst IL-1b plays
a number of physiological roles in the CNS (see Goshen et al., 2007;
Pinteaux et al., 2009; Spulber et al., 2009), excessive production of
this cytokine, particularly in the context of microglial activation,
has been implicated in the neurodegenerative process (see Allan
et al., 2005; Basu et al., 2004 for review). IL-1b signals by binding
to the IL-1 type I receptor (IL-1RI) and recruitment of IL-1 receptor
accessory protein (IL-1RAcp) (Sims et al., 1998; Korherr et al., 1997),
and this signalling system is present in the CNS (Ericsson et al.,
E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e48381995; Lynch and Lynch, 2002). The actions of IL-1b can be regulated
by interleukin-1 receptor antagonist (IL-1ra), which prevents IL-1b
from acting on the IL-1 type I receptor (IL-1RI) (Carter et al., 1990),
and by the IL-1 type II receptor (IL-1RII); a decoy receptor that
serves to sequester IL-1 (Colotta et al., 1994). Both IL-1ra and IL-1RII
are expressed in brain (Pinteaux et al., 2002, 2006), and these
molecules are known to prevent excessive or prolonged activation
of the IL-1 system (Arend, 2002; Bessis et al., 2000), thus increased
expression of these two molecules may serve to combat the dele-
terious effects of IL-1b on brain function.We recently demonstrated
that noradrenaline induces expression of IL-1ra and IL-1RII in
primary glial cells without altering expression of IL-1b, and the
ability of noradrenaline to increase IL-1ra and IL-1RII was mediated
via b-adrenoceptor activation (McNamee et al., 2010a).
Despite the established anti-inflammatory actions of
noradrenaline and b-adrenoceptor agonists on glial cell activation
in vitro (Dello Russo et al., 2004; Mori et al., 2002; McNamee et al.,
2010a), and the role of endogenous noradrenaline in limiting CNS
inflammation in vivo (Feinstein et al., 2002; Heneka et al., 2002;
Kalinin et al., 2007), the anti-inflammatory potential of agents
that enhance central noradrenergic tone, or directly activate central
b2-adrenoceptors have been little examined to date. Recent data
from our laboratory demonstrates that noradrenaline reuptake
inhibitors (NRIs) reduce neuroinflammation following a systemic
inflammatory challenge (O’Sullivan et al., 2009, 2010). In the
present study we assessed the ability of the NRI reboxetine, alone
and in combination with the a2-adrenoceptor antagonist idazoxan,
to impact upon expression of IL-1b, its receptors (IL-1RI, IL-1Racp
and IL-1RII) and IL-1ra in rat cortex. Reboxetine is an antidepres-
sant drug that increases noradrenaline availability by blocking its
reuptake via the noradrenaline transporter (Burrows et al., 1998;
Wong et al., 2000). Idazoxan is an antagonist of inhibitory pre-
synaptic a2-adrenoceptors and greatly augments the ability of
reboxetine to increase the synaptic availability of noradrenaline in
rat brain (Sacchetti et al., 1999). Due to the key role of b2-adreno-
ceptors in meditating the actions of noradrenaline on inflammatory
events in the brain (Mori et al., 2002), we assessed the role of b-
adrenoceptor activation in the ability of reboxetine/idazoxan to
activate the IL-1 system. Furthermore, we assessed the ability of the
b2-adrenoceptor agonists clenbuterol and formoterol to induce
expression of IL-1 system components in the brain. Clenbuterol and
formoterol are bronchodilators used to treat respiratory disorders
including asthma and chronic obstructive pulmonary disease
(Baronti et al., 1980; Boner et al., 1988; Humbert et al., 2008; Papiris
et al., 1986; Steiropoulos et al., 2008), and clenbuterol has been
shown to have neuroprotective properties both in vitro and in vivo
(Culmsee et al., 1999a,b; Gleeson et al., submitted for publication).
As neurodegenerative diseases are associated with a neuro-
inflammatory state (see Block et al., 2007; Heneka and O’Banion,
2007) we determined if b2-adrenoceptor activation could induce
central IL-1ra and IL-1RII expression in the presence of an inflam-
matory stimulus (systemic challenge with bacterial lipopolysac-
charide; LPS). We also determined if b2-adrenoceptor stimulation
could combat the more generalised neuroinflammatory response
induced by LPS administration. Specifically, we examined the ability
of clenbuterol to suppress LPS-induced expression of inflammatory
cytokines IL-1b, TNF-a and IL-6, chemokines RANTES and IP-10 and
co-stimulatory molecules CD40 and ICAM-1.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats (200e250 g) were obtained from Harlan, UK. Rats
were maintained on a 12 h light:12 h dark cycle (lights on at 08:00 h) in a temper-
ature controlled room (22 2 C) and food and water were available ad libitum. Theexperimental protocols were in compliance with the European Communities
Council directive (86/609/EEC).
2.2. Drugs
Reboxetine, idazoxan, clenbuterol and formoterol were obtained from Tocris
Bioscience, UK. Propranolol, dexamethasone and lipopolysaccharide (Escherichia coli:
serotype0111:B4)were obtained fromSigma-Aldrich, Ireland.All drugsweredissolved
in 0.9%NaCl and administeredvia the intraperitoneal (i.p.) route in an injectionvolume
of 1 ml/kg and 0.9% NaCl was administered alone as a vehicle to control animals.
2.3. Experimental design
2.3.1. Experiment I: effect of combined treatment with reboxetine and idazoxan
on IL-1b, IL-1ra, IL-1RI, IL-1Racp and IL-1RII expression in rat cortex
This experiment was conducted to test the hypothesis that increasing central
noradrenergic tone using combined treatment with the NRI reboxetine and the
a2-adrenoceptor antagonist idazoxan could induce expression of the anti-inflam-
matory components of the IL-1 system, IL-1ra and IL-1RII in rat brain. We chose the
cortex for analysis in this study as an in vivo comparator to our in vitro study where
we show that noradrenaline and b-adrenoceptor agonists induces expression of IL-
1ra and IL-1RII in glial cells prepared from rat cortex (McNamee et al., 2010a). In
addition, the cortex receives rich noradrenergic input from the dorsal bundle arising
from the locus coeruleus (Dahlström and Fuxe, 1964), and we have shown that
noradrenaline reuptake inhibitors (NRIs) elicit anti-inflammatory actions in rat
cortex (O’Sullivan et al., 2009). Moreover the cortex is involved in higher cognitive
processing and is adversely affected in many neurodegenerative diseases (Burton
et al., 2004; Whitwell et al., 2007).
The drug treatment regimen employed here was chosen based on its ability to
increase extracellular noradrenaline concentrations in the CNS following acute
administration. Specifically, combined treatment with reboxetine (15 mg/kg; i.p.)
and idazoxan (1 mg/kg; i.p.) has been shown to elicit a robust increase in extra-
cellular noradrenaline in rat cortex (Sacchetti et al., 1999).
Reboxetine (15 mg/kg), Idazoxan (1 mg/kg), or both drugs in combination were
administered intraperitoneally (i.p.), and rats (n¼ 6 per group) were killed 4 h later.
0.9% NaCl was administered to control animals as a vehicle treatment. The brainwas
dissected on an ice-cold plate and a portion of cortical tissue was harvested and
placed into microtubes containing RNA later (Ambion, UK) to ensure integrity of
RNA for gene expression analysis. Another portion of cortex was rapidly frozen on
dry ice in order to facilitate protein analysis. Samples were stored at 80 C until
mRNA expression or protein analysis was performed.
2.3.2. Experiment II: can pre-treatment with the b-adrenoceptor antagonist
propranolol block the ability of reboxetine/idazoxan treatment to activate
the central IL-1 system?
Rats were pre-treated with either vehicle or the b-adrenoceptor antagonist
propranolol (10 mg/kg; i.p.) 30 min prior to administration of reboxetine (15 mg/kg;
i.p.)/idazoxan (1 mg/kg; i.p.) combination treatment. Rats were killed 4 h later and
brain tissue was prepared and stored for analysis of IL-1b, IL-1ra and IL-1RII
expression as outlined in Experiment I above.
2.3.3. Experiment III: can treatment with the brain penetrant b2-adrenoceptor
agonist clenbuterol activate the central IL-1 system?
(a) A time-course analysis: vehicle or clenbuterol (0.5 mg/kg; i.p.) was adminis-
tered to rats and separate groups of rats were killed 1, 4 or 8 h following
clenbuterol treatment. Brain tissue was prepared and stored as outlined in
Experiment I above for measuring expression of IL-1 ligands (IL-1b and IL-1ra),
IL-1 receptors (IL-1RI, IL-1RAcp, IL-1RII), IL-1 signalling (IkBa expression, MAP
Kinase activation and CINC-1 expression), expression of other pro-inflamma-
tory cytokines including IL-6, TNF-a and IFN-g, and of apoptotic markers
including caspase-3, bax and bcl-2. A dose of clenbuterol (0.5 mg/kg) was used
based on studies demonstrating that this dose has neuroprotective effects in
a rat model of stroke (Zhu et al., 1999) and against kainic acid-induced
neurotoxicity (Gleeson et al., submitted for publication).
(b) A doseeresponse analysis: vehicle or clenbuterol (0.03e0.3 mg/kg; i.p.) was
administered to rats which were killed 4 h later, and brain tissue was prepared
and stored as outlined in Experiment I above for analysis of IL-1b, IL-1ra and IL-
1RII expression.2.3.4. Experiment IV: can pre-treatment with the b-adrenoceptor antagonist
propranolol block the ability of clenbuterol to activate the central IL-1 system?
Rats were pre-treated with either vehicle or the brain penetrant b-adrenoceptor
antagonist propranolol (10 mg/kg; i.p.) 30 min prior to clenbuterol (0.5 mg/kg; i.p.)
treatment. Rats were killed 4 h later and brain tissue was prepared and stored as
outlined in Experiment I above for analysis of expression of IL-1b, IL-1ra, IL-1RII and
IkBa expression.
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formoterol mimic the ability of clenbuterol to activate the central IL-1 system?
Vehicle or formoterol (0.5 mg/kg; i.p.) was administered to rats which were
killed 4 h later. Brain tissue was prepared and stored as outlined in Experiment I
above for analysis of IL-1b, IL-1ra, IL-1RII and IkBa expression.
2.3.6. Experiment VI: effect of clenbuterol treatment on neuroinflammation
induced by a systemic LPS challenge
Rats received either vehicle or clenbuterol (0.03 mg/kg; i.p.) co-administered
with LPS (250 mg/kg; i.p.) and were killed 4 h later. Brain tissue was prepared and
stored as outlined in Experiment I above for analysis of a range of markers of
neuroinflammation.
We have previously found that this dose and route of administration of LPS
produces quantifiable increases in cytokine, chemokine and co-stimulatory mole-
cule expression in the CNS (O’Sullivan et al., 2009, 2010). This is a sub-septic dose of
LPS that is approximately 10-fold lower than the LD50 (Hawes et al., 1992) and
provokes modest stimulation of the immune response in rats, characterised by
a transient increase in inflammatory mediator production.
2.4. Analysis of markers of neuroinflammation and neurodegneration
using real-time PCR
RNA was extracted from brain tissue using the NucleoSpin RNA II total RNA
isolation kit (Macherey-Nagel, Germany). Any genomic DNA contamination was
removed with the addition of DNase to the samples according to the manufacturer’s
instructions. RNA was reverse transcribed into cDNA using a High Capacity cDNA
Archive Kit (Applied Biosystems, Darmstadt, Germany). Real-time PCR was per-
formed using an ABI Prism 7300 instrument (Applied Biosystems) as previously
described (Boyle & Connor, 2007). Taqman Gene Expression Assays (Applied Bio-
systems) containing forward and reverse primers and a FAM-labeled MGB Taqman
probewere used to quantify each gene of interest. Assay ID’s for the genes examined
were as follows: IL-1b (Rn00580432_m1), IL-1ra (Rn00573488_m1), IL-1RI
(Rn00565482_m1), IL-1RII (Rn00588589_m1), IL-1RAcp (Rn00492642_m1), IkBa
(Rn01473658_g1), TNF-a (Rn99999017_m1), IFN-g (Rn00594078_m1), IL-6 (Rn005
61420_m1), CD40 (Rn01423583_m1), CINC-1 (Rn00578225_m1), IP-10
(Rn00594648_m1), RANTES (Rn00579590_m1), ICAM-1 (Rn00564227_m1), bax
(Rn02532082_g1), bcl-2 (Rn99999125_m1), caspase-3 (Rn00563902_m1). PCR was
performed using Taqman Universal PCR Master Mix and samples were run in
duplicate. The cycling conditions consisted of 90 C for 10 min and 40 cycles of 90 C
for 15 s followed by 60 C for 1 min. b-actin was used as an endogenous control to
normalize gene expression data. Relative gene expression was calculated using the
DDCT method with Applied BioSystems RQ software (Applied BioSystems, UK).
2.5. Analysis of MAP kinase phosphorylation using Western Immunoblotting
Brain tissue was lysed in ice-cold Hepes lysis buffer (Hepes (25 mM), MgCl2
(5 mM), EDTA (5 mM) in d.d.H2O) with the addition of DTT (5 mM) and 1% (v/v) of
both protease/phosphatase inhibitors (Sigma, UK). The resultant lysate was assayed
for protein content using a BCA protein assay (Pierce) and diluted to give equal
protein concentrations. Samples were diluted 1:1 in sample buffer (0.5 mM
TriseHCl, pH 6.8; 10% glycerol v/v; 10% SDS w/v, 5% 2 b-mercaptoethanol v/v, 0.05%
bromophenol blue w/v) and boiled for 5 min prior to loading onto 10% SDS-poly-
acrylamide gels. Proteins were separated by application of a constant voltage of
30 mA for 25e35 min and transferred onto PVDF membranes (225 mA for 85 min).
To assess the expression of specific proteins, membranes were incubated overnight
at 4 C in 10 ml TBS/Tween (0.1% v/v) containing 1% BSA with one of the following
antibodies: pERK (Santa Cruz Biotechnology; Diluted 1:1000), ERK (Cell Signalling
Technologies; Diluted 1:1000), pP38 (Cell Signalling Technologies; Diluted 1:1000),
P38 (Cell Signalling Technologies; Diluted 1:1000), JNK (Cell Signalling Technolo-
gies; Diluted 1:1000); pJNK (Cell Signalling Technologies; Diluted 1:750). Following
washing, immunoreactive bands were detected by incubating blots with either
peroxidase-linked donkey anti-rabbit IgG (Amersham Biosciences; 1:10,000) or
peroxidase-linked goat anti-mouse IgG (Sigma, UK; 1:10,000), where appropriate, in
10 ml TBS/Tween (0.1% Tween-20 v/v) containing 1% BSA for 1 h at room
temperature.
Blots were exposed to Immobilon Western HRP substrate (Millipore) for 5 min
and developed using an automated developer (Agfa CP1000). Bands were quantified
by densitometric analysis using Gelworks ID, Version 2.51. Gelworks provides
a single value (in arbitrary units) representing the density of each band. Blots were
stripped using Re-Store Western Blot Stripping Buffer (Pierce) prior to re-probing.
2.6. Analysis of IL-1b concentrations by ELISA
IL-1b concentrations were measured in cortical tissue lysates using ELISA with
cytokine specific antibodies and standards (R&D systems, UK). Assays were per-
formed according to the manufacturer’s instructions, and absorbance read at
450 nm using a microplate reader (Biotek instruments). Absorbance was then
recalculated as a concentration (pg/ml) using a standard curve derived using
GraphPad Prism Software Version 4.00 (GraphPad software, Inc).2.7. Statistical analysis of data
All values are expressed as mean standard error of the mean (S.E.M). Data was
analysed using a Student’s t-test or a one- or two-way analysis of variance (ANOVA)
followed, where appropriate, by a NewmaneKeuls post-hoc test (GB-Stat). A value of
P< 0.05 was considered statistically significant.
3. Results
3.1. Enhancement of the central noradrenergic tone induces
expression of IL-1b and its negative regulators IL-1ra and
IL-1RII in rat cortex: a role for b-adrenoceptor activation
Combined treatment with reboxetine and idazoxan induces IL-1b,
IL-1ra and IL-1RII expression: despite our recent finding that in vitro
exposure of primary mixed glial cells to noradrenaline increases
expression of IL-1ra and IL-1RII via activation of b-adrenoceptors
(McNamee et al., 2010a), there is a paucity of research regarding the
potential anti-inflammatory effects of pharmacological agents that
enhance central noradrenergic tone in vivo. Consequently, in this
study we assessed the impact of treatment with the NRI reboxetine
(15 mg/kg; i.p.) and the a2-adrenoceptor antagonist idazoxan
(1 mg/kg; i.p.), alone or in combination, on expression of ligands
and receptors of the IL-1 cytokine system in rat cortex. Specifically,
we examined expression of the pro-inflammatory cytokine IL-1b,
the anti-inflammatory cytokine IL-1ra, IL-1RI and IL-1RAcp through
which IL-1b signals, and IL-1RII; a decoy receptor with anti-
inflammatory properties.
Combined treatment with reboxetine (15 mg/kg; i.p.) and ida-
zoxan (1 mg/kg; i.p.) induced a robust increase in IL-1b (P< 0.001),
IL-1ra (P< 0.05) and IL-1RII (P< 0.001) expression in rat cortex
(Fig. 1A, B and E), without altering IL-1RI or IL-1RAcp expression
(Fig. 1C and D). Consistent with the fact that acute treatment with
idazoxan alone does not increase noradrenaline release (Sacchetti
et al., 1999), idazoxan treatment failed to induce the expression
of IL-1ra, IL-1RI, IL-1II or IL-1RAcp. However, consistent with the
fact that treatment with reboxetine alone provokes a modest
increase in extracellular noradrenaline concentrations (Sacchetti
et al., 1999), reboxetine induced a modest increase in cortical IL-
1b expression (Fig. 1A; P< 0.05) but failed to alter IL-1ra, IL-1RII, IL-
1RI or IL-1RAcp expression (Fig. 1BeE).
b-adrenoceptors mediate the increase in IL-1b, IL-1ra and IL-1RII
induced by combined treatment with reboxetine and idazoxan: pre-
treatment with the b-adrenoceptor antagonist propranolol (10 mg/
kg; i.p.), blocked the increase of IL-1b (P< 0.01), IL-1ra (P< 0.05)
and IL-1RII (P< 0.01) induced by combined treatment with
reboxetine and idazoxan (Fig. 2).
3.2. Direct stimulation of b2-adrenoceptors activates
the central IL-1 system
Clenbuterol induces expression of IL-1b, IL-1ra and IL-1RII in rat
cortex: treatment with the brain penetrant b2-adrenoceptor agonist
clenbuterol (0.5 mg/kg; i.p.), induced a time-dependent increase in
cortical IL-1b (P< 0.01), IL-1ra (P< 0.001) and IL-1RII (P< 0.001)
expression (Fig. 3A, B and E), without altering the expression levels
of IL-1RI or IL-1RAcp (Fig. 3C and D). The induction of IL-1bmRNA is
maximal at 1 h post-treatment, while its negative regulators, IL-1ra
and IL-1RII, show a delayed expression profile peaking 4 h post-
treatment (Fig. 3). The results of our doseeresponse study show
that IL-1b, IL-1ra and IL-1RII expression can be induced by doses of
clenbuterol as low as 0.03 mg/kg (Fig. 5).
Clenbuterol induces IL-1b protein expression and signalling in rat
cortex: induction of IL-1bmRNAwas accompanied by increased IL-
1b protein production (P< 0.01; Fig. 4A) and increased expression
of IkBa mRNA expression (P< 0.01; Fig. 4B), which is indirect
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Fig. 1. Combined reboxetine and idazoxan treatment induces IL-1b, IL-1ra and IL-1RIImRNAexpression in rat cortex. Co-treatmentwith reboxetine (15 mg/kg) and idazoxan (1 mg/kg)
induced a significant increase in cortical IL-1b (A) IL-1ra (B) and IL-1RII (E) mRNA expression 4 h later, but failed to alter expression of IL-1RI (C) or IL-1RAcp (D). Data is expressed as
meansþ SEM (n¼ 6). mRNA data is expressed as fold-change vs. saline vehicle. *P< 0.05, **P< 0.01 vs. saline vehicle (one-way ANOVA followed by post-hoc NewmaneKeuls test).
E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e4840readout of NFkB activation. The clenbuterol-induced increase in IL-
1bwas also accompanied by increased activation (phosphorylation)
of the MAP kinase ERK (P< 0.05; Fig. 4E). In contrast, clenbuterol
failed to activate JNK and P38 MAP kinase pathways. This clenbu-
terol-induced increase in IL-1b protein expression and signalling
was accompanied by induction of the IL-1b-inducible gene, CINC-1
(P< 0.01; Fig. 4F).
Clenbuterol fails to induce expression of other pro-inflammatory
cytokines or induce evidence of apoptotic signalling in rat cortex:in contrast to its ability to activate the IL-1 system, clenbuterol
failed to induce expression of other inflammatory cytokines
including TNF-a, IL-6 or IFN-g (Table 1). In fact, clenbuterol induced
a transient suppression of TNF-a and IL-6 expression (Table 1). In
addition, clenbuterol failed to alter expression of the apoptotic
markers, bcl-2, bax or caspase-3 in rat cortex, at any of the time
points assessed (data not shown).
The b-adrenoceptor antagonist propranolol blocks, and the highly
selective b2-adrenoceptor agonist mimics the ability of clenbuterol to
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Fig. 2. b-Adrenoceptors mediate the ability of combined reboxetine and idazoxan
treatment to induce IL-1b, IL-1ra and IL-1RII expression in rat cortex. Pre-treatment
with the b-adrenoceptor antagonist, propranolol (10 mg/kg), attenuated the increase
in cortical IL-1b (A), IL-1ra (B) and IL-1RII (C) expression induced by combined treat-
ment with reboxetine (15 mg/kg) and idazoxan (1 mg/kg). Data is expressed as
meansþ SEM as fold-change vs. saline vehicle (n¼ 6). *P< 0.05, **P< 0.01 vs. saline
vehicle, þP< 0.05, þþP< 0.01 vs. reboxetine/idazoxan (two-way ANOVA followed by
post-hoc NewmaneKeuls test).
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the central IL-1 system is clearly mediated by central b-adreno-
ceptor activation, as the ability of clenbuterol to induce IL-1b
(P< 0.01), IL-1ra (P< 0.01), IL-1RII (P< 0.01) and IkBa (P< 0.05)
was blocked by pre-treatment with the brain penetrant b-adreno-
ceptor antagonist, propranolol (Fig. 6AeD). In addition, the highly
selective b2-adrenoceptor agonist formoterol (0.5 mg/kg; i.p.),
mimicked the ability of clenbuterol to induce IL-1b (P< 0.01), IL-1ra
(P< 0.01), IL-1RII (P< 0.01) and IkBa (P< 0.05) (Fig. 6EeH).
3.3. Clenbuterol attenuates neuroinflammation induced
by a systemic challenge with bacterial LPS
As neurodegenerative diseases are associated with an inflam-
matory state within the CNS (see Allan et al., 2005; Block et al.,
2007; Heneka and O’Banion, 2007) it was important for us to
determine if b2-adrenoceptor activation could induce central IL-1ra
and IL-1RII expression in the presence of an inflammatory stimulus
(a systemic challenge with bacterial lipopolysaccharide; LPS). In
addition, we determined the ability of b2-adrenoceptor stimulation
to combat the more generalised neuroinflammatory response
induced by LPS administration.
The ability of clenbuterol to induce cortical IL-1b expressionwas
attenuated (P< 0.05) in LPS-treated animals (Fig. 7A). In contrast,
the clenbuterol-induced induction of IL-1ra and IL-1RII was not
altered following LPS administration (Fig. 7B and C). Furthermore,
a general anti-inflammatory effect was observed following b2-
adrenoceptor agonist administration as clenbuterol suppressed
LPS-induced expression of the inflammatory cytokines IL-6 and
TNF-a (P< 0.05), the inflammatory chemokines RANTES and IP-10
(P< 0.05) and the co-stimulatory molecules CD40 (P< 0.01) and
ICAM-1 (P< 0.05) in the rat cortex (Fig. 7DeI).
4. Discussion
4.1. Enhancement of noradrenergic tone activates the
central IL-1 system via b-adrenoceptor activation
Here we demonstrate that combined treatment with reboxetine
and idazoxan, a drug combination that induces a robust increase in
central noradrenaline availability (Sacchetti et al., 1999), induced
expression of IL-1b in rat cortex, as well as its negative regulators
IL-1ra and IL-1RII, both of which serve to inhibit IL-1b signalling
and prevent excessive or prolonged activation of the IL-1 system.
Consistent with the fact that idazoxan alone does not increase
noradrenaline release (Sacchetti et al., 1999), it failed to induce IL-
1b, IL-1ra or IL-1RII expression. Whilst treatment with reboxetine
alone induced a slight increase in IL-1b, IL-1ra and IL-1RII expres-
sion this was greatly augmented when reboxetine was adminis-
tered in combination with idazoxan. This observation is consistent
with the profound synergistic increase in noradrenaline release in
rat cortex that occurs when idazoxan and reboxetine are adminis-
tered in combination (Sacchetti et al., 1999). Consistent with a role
for b-adrenoceptors in mediating the immunomodulatory affects of
noradrenaline, the effects of combined reboxetine/idazoxan treat-
ment on the IL-1 system were blocked by pre-treatment with the
b-adrenoceptor antagonist, propranolol.
In contrast to the profound increase in IL-1RII induced by the
reboxetine/idazoxan combination, no significant change in IL-1RI
or IL-1RAcp expression occurred. This is consistent with our in vitro
study, in which noradrenaline failed to alter glial IL-1RI or IL-1RAcp
expression (McNamee et al., 2010a), and with previous research
indicating that the low constitutive levels of IL-1RI expression in
the brain don’t appear to be easily altered, at least in animal models
(Parnet et al., 1994; Gayle et al., 1999).
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Fig. 3. The b2-adrenoceptor agonist, clenbuterol, induces IL-1b, IL-1ra and IL-1RII mRNA expression in rat cortex: a time-course analysis. Treatment with the selective b2-adre-
noceptor, clenbuterol (0.5 mg/kg), induces a time-dependent increase in cortical IL-1b (A) IL-1ra (B) and IL-1RII (E) mRNA expression, but failed to alter expression of IL-1RI (C) or IL-
1RAcp (D). Data is expressed as meansþ SEM (n¼ 6). mRNA data is expressed as fold-change vs. saline vehicle. *P< 0.05, **P< 0.01 vs. saline vehicle (one-way ANOVA followed by
post-hoc NewmaneKeuls test).
E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e48424.2. Direct stimulation b2-adrenoceptors selectively
activates the central IL-1 system
It is clear from the present study that treatment with the brain
penetrant b2-adrenoceptor agonist clenbuterol mimicked the
ability of reboxetine/idazoxan treatment to induce IL-1b, IL-1ra and
IL-RII expression in rat cortex. However, the magnitude of increase
was much greater than observed with reboxetine/idazoxan treat-
ment, most likely due to the low agonist potency of noradrenaline
at b2-adrenoceptors relative to selective b2-adrenoceptor agonists.
Clenbuterol’s actions were selective to the IL-1 system, in that
expression of the inflammatory cytokines TNF-a, IL-6 or IFN-gwere
not induced by clenbuterol. Instead, clenbuterol treatment induced
a transient suppression of TNF-a and IL-6 expression. This is an
important finding as the neurotoxic actions of IL-1b are muchmore
likely to emerge when it is expressed in concert with other
inflammatory mediators.
Induction of IL-1b was accompanied by NFkB activation, indi-
cated by increased expression of the proto-typical NFkB inducible
gene IkBa (Read et al., 1994), and expression of the IL-1b-inducible
gene, CINC-1 (Anthony et al., 1998). In addition to activating the
NFkB pathway, IL-1 is known to activate MAP kinase pathways
(Saklatvala et al., 1996). In this regard, the clenbuterol-induced
increase in IL-1b was accompanied by increased activation (phos-
phorylation) of the MAP kinase ERK; a signalling pathway associ-
ated with pro-survival effects in neurons (Fukunaga andMiyamoto,
1998). In contrast, clenbuterol failed to activate JNK and P38 MAP
kinase pathways, both of which have been implicated in mediatingdetrimental effects of IL-1 and glial cell activation in the brain
(Curran et al., 2003; Kelly et al., 2001; Martin et al., 2002; Minogue
et al., 2003; Xie et al., 2004). Consistent with this, clenbuterol failed
to alter expression of the apoptotic markers, bcl-2, bax or caspase-3
in rat cortex, at any of the time points assessed (data not shown). It
is important to note that activation of IL-1 signalling, observed
following b-adrenoceptor stimulation, occurred in a tightly
controlled manner. Specifically, expression of IL-1ra and IL-1RII
serve to inhibit prolonged IL-1 signalling which could be delete-
rious for brain function. In this regard, the increase in expression of
the IL-1b-inducible gene, CINC-1, had completely dissipated 8 h
following clenbuterol treatment.
The ability of clenbuterol to activate the IL-1 systemwas blocked
by propranolol, and was mimicked by the highly selective b2-
adrenoceptor agonist formoterol. These data are important in
highlighting the specific role of b-adrenoceptor activation in the
actions of clenbuterol on the central IL-1 system, as previous
studies indicate that clenbuterol can elicit biological responses
independent of b-adrenoceptors (Desaphy et al., 2003; Ngala et al.,
2009). Our finding that systemic administration of clenbuterol
induces IL-1b expression in brain tissue, is consistent with studies
reporting that icv administration of the b-adrenoceptor agonists
isoprenaline and procaterol induced IL-1b expression from glial
cells in rat brain parenchyma (Johnson et al., 2008; Maruta et al.,
1997). However, to our knowledge this is the first study to
demonstrate that b-adrenoceptors mediate induction of IL-1ra and
IL-1RII expression in the brain. Whilst the present investigation
focuses specifically on the actions of b2-adrenoceptors in rat cortex,
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Fig. 4. The b2-adrenoceptor agonist, clenbuterol, induces IL-1b protein expression and signalling rat cortex: a time-course analysis. Treatment with the selective b2-adrenoceptor,
clenbuterol (0.5 mg/kg), induced a time-dependent increase in cortical IL-1b protein as measured by ELISA (A). This increase in IL-1b protein was accompanied by increased IkBa
expression indicative of NFkB activation (B), activation of the MAP kinase ERK (E) and induction of the IL-1b-inducible gene CINC-1 (F). In contrast, clenbuterol did not activate the
MAP kinases P38 and JNK (C,D). Data is expressed as meansþ SEM (IL-1b protein expression and IkBa, CINC-1 and iNOS mRNA n¼ 6; MAP kinase phosphorylation densitometry
n¼ 4). mRNA data is expressed as fold-change vs. saline vehicle. *P< 0.05, **P< 0.01 vs. saline vehicle (one-way ANOVA followed by post-hoc NewmaneKeuls test).
E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e48 43we have recently demonstrated that clenbuterol also induces
expression of IL-1b, IL-1ra and IL-1RII in rat hippocampus and
hypothalamus (Griffin et al., in press). In contrast to these in vivo
observations, noradrenaline and b-adrenoceptor agonists both fail
to induce IL-1b expression in cultured glial cells (Kilroy, unpub-
lished results; McNamee et al., 2010a). The reason for this
discrepancy between in vitro and in vivo systems remains to be
elucidated.It is noteworthy that the increase in IL-1Ra and IL-1RII induced by
clenbuterol do not occur simply as a downstream consequence of
clenbuterol-induced IL-1b production. In this regard,wehave shown
that the anti-inflammatory agent dexamethasone completely blocks
expression of IL-1b induced by clenbuterol, without altering its
ability to induce the anti-inflammatory molecules IL-1ra and IL-1RII
(Griffin et al., in press). These data highlight are consistent with
previous observations that IL-1ra and IL-1RII expression can occur
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Table 1
Effect of treatment with the b2-adrenoceptor agonist clenbuterol on expression of
the pro-inflammatory cytokines TNF-a, IL-6 and IFN-g in rat cortex.
Vehicle Clenbuterol (0.5 mg/kg) Hours
post-treatment
P value
1 4 8
TNF-a 1.0 0.10 0.26 0.05** 0.88 0.06 1.30 0.16 P< 0.001
IL-6 1.0 0.02 0.35 0.07* 0.99 0.15 0.79 0.14 P¼ 0.018
IFN-g 1.0 0.27 1.30 0.31 1.14 0.19 1.03 0.15 P¼ 0.808
Data expressed as fold-change of the mean mRNA expression S.E.M. vs. saline
vehicle (n¼ 6).
*P< 0.05, **P< 0.01 vs. saline vehicle (one-way ANOVA followed by post-hoc
NewmaneKeuls test).
E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e4844independent of IL-1b both in cultured glial cells and in the intact
brain (Docagne et al., 2005; McNamee et al., 2010a).
4.3. b-Adrenoceptor-mediated activation of the central
IL-1 system: implications for brain function
There is now a general consensus that inflammatory mediators
including IL-1b can exert both adaptive and maladaptive responses
in the brain, depending on the concentration, the duration of
exposure and the overall immune environment (Goshen et al.,
2007; Li et al., 2007; Pinteaux et al., 2009; Spulber et al., 2009).
For instance, whilst administration of exogenous IL-1b has been
shown to inhibit memory and learning and block hippocampal
long-term potentiation (LTP); an electrophysiological process
thought to underline memory formation (Kelly et al., 2003; Pugh
et al., 2001), constitutive expression of IL-1 is required for normal
learning and memory and LTP (Avital et al., 2003; Goshen et al.,
2007). Similarly, whilst there is a body of research outlining the
contribution of IL-1b to the neurodegenerative process (Allan et al.,
2005), evidence also indicates that IL-1bmay elicit neuroprotective
effects both in vitro and in vivo. For example, IL-1b protected
cultured cortical neurons in an NMDA-induced in vitro model of
excitotoxicity (Strijbos and Rothwell, 1995), and enhanced survival
of lesioned cultured dopaminergic neurons (Akaneya et al., 1995).
In the in vivo context, IL-1b infusion into the substantia nigra 5 days
prior to 6-hydroxydopamine administration elicits neuroprotective
effects in this model of Parkinson’s disease (Saura et al., 2003), and
sustained overexpression of hippocampal IL-1b ameliorates
amyloid-b (Ab) plaque pathology in a mouse model of Alzheimer’s
disease (Shaftel et al., 2007). In line with this finding, IL-1b drives
amyloid precursor protein processing in a non-amyloidogenic
direction resulting in decreased Ab production (Tachida et al.,
2008). Finally, it has been shown that remyelination is dramati-
cally reduced in the absence of IL-1b (Mason et al., 2001), and that
IL-1b can induce oligodendrocyte proliferation and maturation
(Vela et al., 2002). Taken together, these findings suggest that IL-1b
can elicit protective or detrimental effects in the CNS depending on
the context, and that constitutive expression of IL-1b is necessary
for many aspects of normal brain function. In this regard, whilst
both clenbuterol and noradrenaline reuptake inhibitors have neu-
roprotective (Culmsee et al., 1999a; Gleeson et al., submitted for
publication; Huang et al., 2007; Wang et al., 2007; Zhu et al.,
1999), and memory enhancing properties (Clinton et al., 2006;
Ramos et al., 2008; Seu et al., 2009), any role that IL-1 systemFig. 5. The b2-adrenoceptor agonist, clenbuterol, activates the IL-1 system in rat
cortex: a doseeresponse analysis. Treatment with the selective b2-adrenoceptor
agonist, clenbuterol (0.03e0.3 mg/kg), induced a significant increase cortical IL-1b (A),
IL-1ra (B) and IL-1RII (C) expression 4 h post-treatment. Data is expressed as mean-
sþ SEM as fold-change vs. saline vehicle (n¼ 6). *P< 0.05, **P< 0.01 vs. saline vehicle
(one-way ANOVA followed by post-hoc NewmaneKeuls test).
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Fig. 7. Clenbuterol attenuates neuroinflammation induced by a systemic challenge with bacterial LPS. The b2-adrenoceptor agonist clenbuterol (0.03 mg/kg) induces cortical IL-1ra
(B) and IL-1RII (C) mRNA expression when administered in the presence of the inflammagen bacterial LPS (250 mg/kg). In contrast, the ability of clenbuterol to induce IL-1b
expression was reduced in LPS-treated animals (A). In addition, clenbuterol blocked the LPS-induced induction of inflammatory cytokines IL-6 and TNF-a (D,E), the co-stimulatory
molecules CD40 and ICAM-1 (F,G) and the inflammatory chemokines IP-10 and RANTES (H,I) in rat cortex. Data is expressed as meanþ SEM. mRNA data is expressed as fold-change
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E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e4846components may have in such neuroprotective or memory
enhancing actions of these drugs remains to be elucidated. In
addition, as combined treatment with reboxetine/idazoxan
induced a very modest increase in IL-1b expression when
compared to the large induction of IL-1b induced by b2-adreno-
ceptor agonists or LPS, future studies are required to determine the
functional significance of the different levels of IL-1b induced by
these treatments for brain function.
4.4. Clenbuterol attenuates neuroinflammation
induced by a systemic LPS challenge
As neurodegenerative diseases are associated with an inflam-
matory state within the CNS (see Block et al., 2007; Heneka and
O’Banion, 2007), it was important for us to determine if b-adre-
noceptor activation could induce central IL-1ra and IL-1RII
expression in the presence of an inflammatory stimulus. Consistentwith our in vitro findings (McNamee et al., 2010a) clenbuterol was
also effective at inducing IL-1ra and IL-1RII expression in the brains
of animals that has been treated with a systemic inflammatory
challenge with LPS. Moreover, whilst the ability of clenbuterol to
induce expression of IL-1RII and IL-1Ra was maintained following
the inflammatory challenge, its ability to induce IL-1bwas reduced.
Thus in an inflammatory state clenbuterol has a multifaceted action
on the IL-1 system resulting in its downregulation.
In addition to its actions on the central IL-1 system, clenbuterol
induced a broad spectrum anti-inflammatory response in rat cortex
following exposure to a systemic LPS challenge. Specifically, clen-
buterol suppressed LPS-induced expression of the inflammatory
cytokines TNF-a and IL-6, the inflammatory chemokines RANTES
and IP-10, the co-stimulatory molecules CD40 and ICAM-1. These
molecules mediate different aspects of the neuroinflammatory
response, and have been implicated in the neurodegenerative
process (see O’Sullivan et al., 2009, 2010). The ability of clenbuterol
E.N. McNamee et al. / Neuropharmacology 59 (2010) 37e48 47to suppress the central inflammatory response to LPS is consistent
with studies demonstrating that noradrenaline reuptake inhibitors
suppress expression of inflammatory mediators including TNF-a,
IL-1b, CD40, ICAM-1, IP-10 and RANTES in rat brain following an LPS
challenge (O’Sullivan et al., 2009, 2010). In addition, we have
previously demonstrated that clenbuterol induces expression of
the broad spectrum anti-inflammatory and neuroprotective cyto-
kine IL-10 (McNamee et al., 2010b). Thus overall, both noradrena-
line reuptake inhibitors and b2-adrenoceptor agonists suppresses
the innate inflammatory response in the CNS.
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